Fixing Pharma investment in Canadian R&D a priority

The Big Pharmaceutical companies create medicines and devices for millions of people worldwide while making substantial profits. The Patent Medicines Pricing Review Board’s (PMPRB) 2011 Annual Report highlights that the investment of research and development (R&D) in Canada by these companies has not matched their commitment levels. The association representing the Big Pharma player, Canada’s Research-based Pharmaceutical Companies (Rx&D), pleads that a poor investment environment in Canada needs to be fixed so that they can effectively compete for corporate R&D dollars.

Read More…

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s